Tiangen Chang

Tiangen Chang

Auto-generated profile, based on publicly available information

Tiangen Chang

National Cancer Institute 1 Cancer Data Science Laboratory, Center for Cancer Research National Institutes of Health, Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
TCTian-Gen Chang
Tian-Gen Chang
YCYingying Cao
Yingying Cao
HSHannah J. Sfreddo
Hannah J. Sfreddo
SDSaugato Rahman Dhruba
Saugato Rahman Dhruba
SKSe Hoon Kim
Se Hoon Kim
EREytan Ruppin
Eytan Ruppin

7 March 2025 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
TCTian-Gen Chang
Tian-Gen Chang
SPSeongyong Park
Seongyong Park
ASAlejandro A. Schäffer
Alejandro A. Schäffer
PJPeng Jiang
Peng Jiang
EREytan Ruppin
Eytan Ruppin

9 September 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MIMarica Rosaria. Ippolito
Marica Rosaria. Ippolito
JZJohanna Zerbib
Johanna Zerbib
YEYonatan Eliezer
Yonatan Eliezer
EREli Reuveni
Eli Reuveni
SVSonia Viganò
Sonia Viganò
UBUri Ben-David
Uri Ben-David
Aneuploidy results in a stoichiometric imbalance of protein complexes that jeopardizes cellular fitness. Aneuploid cells thus need to compensate for the imbalanced DNA levels by regulating their RNA and protein levels, but the underlying molecular mechanisms remain unknown. In this study, we dissected multiple diploid versus aneuploid cell models. We found that aneuploid cells cope with transcriptional burden by increasing several RNA degradation pathways, and are consequently more sensitive to the perturbation of RNA degradation. At the protein level, aneuploid cells mitigate proteotoxic stress by reducing protein translation and increasing protein degradation, rendering them more sensitive to proteasome inhibition. These findings were recapitulated across hundreds of human cancer cell lines and primary tumors, and aneuploidy levels were significantly associated with the response of patients with multiple myeloma to proteasome inhibitors. Aneuploid cells are therefore preferentially dependent on several key nodes along the gene expression process, creating clinically actionable vulnerabilities in aneuploid cells. Significance: Aneuploidy is a hallmark of cancer that is associated with poor prognosis and worse drug response. We reveal that cells with extra chromosomes compensate for their imbalanced DNA content by altering their RNA and protein metabolism, rendering them more sensitive to perturbation of RNA and protein degradation. See related commentary by Bakhoum, p. 2315

9 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JZJohanna Zerbib
Johanna Zerbib
MIMarica Rosaria Ippolito
Marica Rosaria Ippolito
YEYonatan Eliezer
Yonatan Eliezer
GFGiuseppina De Feudis
Giuseppina De Feudis
EREli Reuveni
Eli Reuveni
SSStefano Santaguida
Stefano Santaguida
Aneuploidy is a hallmark of human cancer, yet the molecular mechanisms to cope with aneuploidy-induced cellular stresses remain largely unknown. Here, we induce chromosome mis-segregation in non-transformed RPE1-hTERT cells and derive multiple stable clones with various degrees of aneuploidy. We perform a systematic genomic, transcriptomic and proteomic profiling of 6 isogenic clones, using whole-exome DNA, mRNA and miRNA sequencing, as well as proteomics. Concomitantly, we functionally interrogate their cellular vulnerabilities, using genome-wide CRISPR/Cas9 and large-scale drug screens. Aneuploid clones activate the DNA damage response and are more resistant to further DNA damage induction. Aneuploid cells also exhibit elevated RAF/MEK/ERK pathway activity and are more sensitive to clinically-relevant drugs targeting this pathway, and in particular to CRAF inhibition. Importantly, CRAF and MEK inhibition sensitize aneuploid cells to DNA damage-inducing chemotherapies and to PARP inhibitors. We validate these results in human cancer cell lines. Moreover, resistance of cancer patients to olaparib is associated with high levels of RAF/MEK/ERK signaling, specifically in highly-aneuploid tumors. Overall, our study provides a comprehensive resource for genetically-matched karyotypically-stable cells of various aneuploidy states, and reveals a therapeutically-relevant cellular dependency of aneuploid cells.

3 June 2023 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
TCTian-Gen Chang
Tian-Gen Chang
YCYingying Cao
Yingying Cao
ESEldad D. Shulman
Eldad D. Shulman
UBUri Ben-David
Uri Ben-David
ASAlejandro A. Schäffer
Alejandro A. Schäffer
EREytan Ruppin
Eytan Ruppin
Identifying patients that are likely to respond to cancer immunotherapy is an important, yet highly challenging clinical need. Using 3139 patients across 17 different cancer types, we comprehensively studied the ability of two common copy-number alteration (CNA) scores—the tumor aneuploidy score (AS) and the fraction of genome single nucleotide polymorphism encompassed by copy-number alterations (FGA)—to predict survival following immunotherapy in both pan-cancer and individual cancer types. First, we show that choice of cutoff during CNA calling significantly influences the predictive power of AS and FGA for patient survival following immunotherapy. Remarkably, by using proper cutoff during CNA calling, AS and FGA can predict pan-cancer survival following immunotherapy for both high-TMB and low-TMB patients. However, at the individual cancer level, our data suggest that the use of AS and FGA for predicting immunotherapy response is currently limited to only a few cancer types. Therefore, larger sample sizes are needed to evaluate the clinical utility of these measures for patient stratification in other cancer types. Finally, we propose a simple, non-parameterized, elbow-point-based method to help determine the cutoff used for calling CNAs.

17 November 2024 in Annals of Oncology
Verified
Journal Article
Closed access
TCT.-G. Chang
T.-G. Chang
Aris SpathisAris Spathis
Aris Spathis
ASAlejandro A. Schäffer
Alejandro A. Schäffer
NGN. Gavrielatou
N. Gavrielatou
FKF. Kuo
F. Kuo
EREytan Ruppin
Eytan Ruppin